Research and Markets: Wnt Signaling Pathway in Oncology Drug Pipeline Report 2015

Research and Markets (http://www.researchandmarkets.com/research/xmwqkk/wnt_signaling) has announced the addition of the "Wnt Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.

Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone.

There are today 186 companies plus partners developing 189 Wnt pathway targeting drugs in 763 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 115 drugs.

Wnt Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 200 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 196 out of the 197 studied drug targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 41 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs

• Marketed - 12
• Registered - 1
• Pre-registration - 2
• Phase III - 15
• Phase II - 70
• Phase I - 75
• Preclinical - 128
• No Data - 6
• Suspended - 2
• Ceased - 115
  

Delivery Format: Desktop App plus Online Access to Updates (One Year)

For more information visit http://www.researchandmarkets.com/research/xmwqkk/wnt_signaling